~1 in 6 pts with #sarcoidosis May have #cardiac involvemt 1/3 respond to #MTX + #steroids Followed by repeat #PET Failures get 👇 #infliximab >#adalimumab 👇 #JAKi Better survival >yrs ago R heart involved ⬆️risk of MTX nonresponse #ACR25 @RheumNow @ACRheum abst#1664 #ACRbest https://t.co/kYt9JRNSVH

• https://x.com/Janetbirdope/status/1982882247314419752/photo/1
• https://x.com/Janetbirdope/status/1982882247314419752/photo/1

In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, either: - during 1y of treatment - in 2y follow-up https://t.co/gtzNiSmutb but StopRA will give us plenty of insights - data is never wasted #ACR25 ABST1674 @RheumNow https://t.co/DDZib5VGtX

• A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid art…
• https://x.com/drdavidliew/status/1982874509758902603/photo/1

SELECT-COMPARE (upadacitinib vs adallimumab in mod-severe RA, no CV enrichment) 7y data: safety profiles very similar, except for: - zoster - CK rise - lymphopenia - hepatic disorder In the general RA population, no new JAKi safety signals #ACR25 ABST1676 @RheumNow https://t.co/BA2JxONGfa

• https://x.com/drdavidliew/status/1982882215160885563/photo/1

#ACR25 Please find our Day 1 Recap of the conference where we discussed our favourite abstracts and learning points 😃 @Janetbirdope @AurelieRheumo @RheumNow https://t.co/X125tjyqi5

• https://twitter.com/rheumnow/status/1982568313684378002

Abstract 1421: PsA and 'Brain Fog' Pts w/ #PsA who did not achieve Minimal Disease Activity (MDA) had higher odds of subjective cognitive decline vs those with MDA 🔹 Fatigue, and to a lesser extent depression/anxiety, ↓ this associated risk @RheumNow #ACR25 https://t.co/RohwKJZDzp

• https://x.com/AkhilSoodMD/status/1982841468864897256/photo/1
• https://x.com/AkhilSoodMD/status/1982841468864897256/photo/1

In the IMPACT trial (Abs 0855), certolizumab met its primary endpoint: <20% had an adverse pregnancy outcome (APO) among females w/ APS & prior APO. ✅ 94% live births, all survived to discharge 📈 Median GA: 37 wks (no APO) vs 31 wks (APO) @RheumNow #ACR25

Start strong, stay strong. With early anti-TNF induction (vs csDMARD T2T) - At 5 yrs: D2T RA in <1% vs 7% (OR 0.11, p=0.03) Drug-free remission 13% vs 6% (p=0.049) - At 10 yrs: more sustained remission (62% vs 45%) & fewer multi-MoA failures. @RheumNow #ACR25 Abstract #1677

What is the secret of a VNS RCT that works in RA? => Implant the device! RESET-RA RCT Sham controlled 3mo Then open label in active arm for 66mo 40% pts IR to >=3 bioDMARDs ACR 20 3 mo 42% vs. 19% CDAI LDA 27% vs. 11% 82% TNF IR pt had no change in treatment over 12mo 99% https://t.co/lfxa4YXUB4

• https://x.com/AurelieRheumo/status/1982878622647230939/photo/1
• https://x.com/AurelieRheumo/status/1982878622647230939/photo/1
• https://x.com/AurelieRheumo/status/1982878622647230939/photo/1

Implantable vagal stimulator led to benefit in TNF-inadequate responder RA in this sham-controlled double-blind RCT (RESET-RA study) - 82% off b/tsDMARDs at 12mo - also with benefit to control group after crossover at 3mo to an active device #ACR25 1675 @RheumNow https://t.co/yYwWCKm6HF

• https://x.com/drdavidliew/status/1982878593199026656/photo/1

Did we need a 2nd Interception RCT of HCQ in Pre-RA? Unsure but in any case, it does not work either STOPRA CCP3+>=2 ind 71 HCQ and 74 PBO 36 months RA conversion Dr Deane's take: "probably wrong drug rather than wrong timing" #ACR25 @RheumNow #ABSTRACT1674 https://t.co/jysdo8iz7v

• https://x.com/AurelieRheumo/status/1982874833257152964/photo/1

New tx for IPF/autoimmune ILD, nerandomilast (PDE4Bi) Subgroup analysis from FIBRONEER-ILD, marginally less FVC worsening (-65mL tx grp vs -107mL plbo grp) & no clear improvements in dyspnea/fatigue/cough But also... 6% absolute reduction in overall, persisted (small n) in https://t.co/Faf26UZuDx

• https://x.com/EBRheum/status/1982870661690237240/photo/1
• https://x.com/EBRheum/status/1982870661690237240/photo/1
• https://x.com/EBRheum/status/1982870661690237240/photo/1

In the SERENA study (n=292), secukinumab reduced PsA incidence to 0.49/100 PY over 5 years in PsO patients with nail involvement, an ~82% drop vs historic non-biologic rates (2.7/100 PY). 98.3% remained PsA-free; PASI 90 achieved in 63%. Abstract#1463 @RheumNow #ACR25 https://t.co/ySOuFJiwge

• https://x.com/synovialjoints/status/1982869912092619021/photo/1

Like PEXIVAS steroid taper, this is something we need an online resource to check each time. Its complicated, but feels "right". @RheumNow #ACR25 https://t.co/QAgSQB9XMQ

• https://twitter.com/Yuz6Yusof/status/1982823893199880429

#ACR25 SMILE RCT of Incomplete #SLE (ANA+ but not meeting SLICC) showed HCQ didn’t slow down SLE progression. But multiplex arrays showed reduction in autoantibodies with HCQ that were distinct from abs assoc. w progression. Would biomarker endpoints be the answer? @RheumNow https://t.co/XcvacgObVo

• https://x.com/Yuz6Yusof/status/1982864787144093994/photo/1